Diagnosis and Management of the Cardiac Amyloidoses
By R. Falk. Circulation, 2005
745 citations recorded by the source corpus.
Subfields: Molecular Biology, Nephrology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/b668ea94634de67fce364039b079fce866d8a76e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types (2009, neutral): “LV ejection fraction 40%, n (%) 34 (22) 5 (8)‡ 6 (40) 0.”
- HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). (2011, background): “Although there are several genes in which mutations have been reported to cause amyloidosis, familial cardiac amyloid is most commonly caused by mutations in TTR, which encodes transthyretin.(250) Although transthyretin amyloidosis occurs without race or gender predilection, certain TTR mutations ar”
- The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. (2007, background): “Senile, transthyretin-associated, and primary (AL) amyloidosis may have cardiac involvement that results in a dilated, restrictive, or hypertrophic pattern of cardiomyopathy (124).”
- Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis (2016, neutral): “Echocardiography, although a valuable and widely accessible tool for investigating heart failure, is neither sensitive nor specific for cardiac amyloidosis.(10) Typical findings on echocardiography include thickening of ventricular walls, restrictive filling, abnormal left and right ventricular long”